Akorn, Inc.  

(Public, NASDAQ:AKRX)   Watch this stock  
Find more results for AKRX
+0.02 (0.06%)
Real-time:   2:06PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.58 - 33.68
52 week 17.61 - 35.40
Open 33.66
Vol / Avg. 2.65M/1.94M
Mkt cap 4.20B
P/E 23.00
Div/yield     -
EPS 1.46
Shares 124.76M
Beta 1.36
Inst. own 84%
Jul 19, 2017
Akorn Inc Extraordinary Shareholders Meeting
May 4, 2017
Q1 2017 Akorn Inc Earnings Release
Apr 27, 2017
Akorn Inc Annual Shareholders Meeting
Apr 25, 2017
Fresenius SE & Co KGaA On The Acquisition Of Akorn And Merck KGaA's Biosimilars Business - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 16.19% 16.50%
Operating margin 29.53% 29.33%
EBITD margin - 40.87%
Return on average assets 8.23% 9.17%
Return on average equity 19.48% 25.58%
Employees 2,261 -
CDP Score - -


1925 W Field Ct Ste 300
LAKE FOREST, IL 60045-4862
United States - Map
+1-847-2796100 (Phone)
+1-800-9433694 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a range of dosage forms, including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals and nasal sprays and otics. The Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. Its branded and private-label OTC products are focused on ophthalmics, including a dry eye treatment TheraTears Therapy for Your Eyes.

Officers and directors

John N. Kapoor Ph.D. Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Rajat Rai Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Duane A. Portwood Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Bruce Kutinsky Ph.D. Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Joseph P. Bonaccorsi Executive Vice President, General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
Jonathon Kafer Executive Vice President - Sales and Marketing
Age: 53
Bio & Compensation  - Reuters
Steven Joseph Lichter Executive Vice President - Pharmaceutical Operations
Age: 58
Bio & Compensation  - Reuters
Randall E. Pollard Senior Vice President, Chief Accounting Officer, Corporate Controller
Age: 45
Bio & Compensation  - Reuters
Brian Tambi Director
Age: 71
Bio & Compensation  - Reuters
Kenneth S. Abramowitz Independent Director
Age: 66
Bio & Compensation  - Reuters